-+ 0.00%
-+ 0.00%
-+ 0.00%
enVVeno Medical's VenoValve Shows Sustained Clinical Benefits in Three-Year Study Data
Share
Listen to the news
enVVeno Medical's VenoValve Shows Sustained Clinical Benefits in Three-Year Study Data
  • enVVeno Medical will present three-year results from its VenoValve pivotal study today at the VEITH Symposium in New York.
  • Patients with severe chronic venous insufficiency showed sustained, statistically significant improvements in disease severity, leg pain and quality of life.
  • The next-generation enVVe valve is designed for less invasive implantation under light sedation, with patients expected to return home the same day.
  • The FDA authorized the enVVe pivotal trial in April 2026; enrollment of the first patient remains on track for year-end 2026.
  • The trial will initially monitor safety in up to 10 patients before FDA review determines progression to its second stage.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enVVeno Medical Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611200841ACCESSWRNAPR_____1254610) on November 20, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending